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ABSTRACT 
We have investigated the requirement for signaling at CB1 receptors in the reconsolidation of a previously 
consolidated auditory fear memory, by infusing the CB1 receptor antagonist AM251, or the FAAH inhibitor 
URB597, directly into the basolateral amygdala (BLA) in conjunction with memory reactivation. AM251 
disrupted memory restabilisation, but only when administered post-reactivation. URB597 produced a small, 
transient enhancement of memory restabilisation when administered post-reactivation. The amnestic 
effect of AM251 was rescued by co-administration of the GABAA receptor antagonist bicuculline at 
reactivation, indicating that the disruption of reconsolidation was mediated by altered GABAergic 
transmission in the BLA. These data show that the endocannabinoid system in the BLA is an important 
modulator of fear memory reconsolidation and that its effects on memory are mediated by an interaction 
with the GABAergic system. Thus, targeting the endocannabinoid system may have therapeutic potential to 
reduce the impact of maladaptive memories in neuropsychiatric disorders such as post-traumatic stress 
disorder. 
Keywords: behavioral science, cannabinoids, learning & memory, mood / anxiety / stress disorders, 
reconsolidation, conditioned fear, PTSD, rat 
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INTRODUCTION 
Memory reconsolidation is the process by which a well-consolidated memory returns to a labile state and 
becomes susceptible to manipulation (Lewis, 1979; Nader, 2003). This process has been extensively 
investigated in the context of pavlovian conditioned fear memories, where pharmacological manipulation 
at memory reactivation can prevent (Dębiec et al, 2002; Milton et al, 2013; Nader et al, 2000) or enhance 
(Lee et al, 2006) the subsequent expression of the conditioned fear response. Thus, it has been argued that 
targeting the reconsolidation process may provide a novel means of disrupting maladaptive memories in 
neuropsychiatric disorders such as post-traumatic stress disorder (PTSD; Brunet et al, 2008; Schiller et al, 
2010), persistently reducing symptoms of the disorder following only a single (or few) treatment sessions 
combining behavioral and pharmacological therapy. However, any amnestic agent used in the clinic ideally 
should not also have adverse side effects; therefore, identifying new drug targets for disrupting memory 
reconsolidation is of critical importance in translating these promising findings to the clinic.  
 
Drugs that alter levels of endogenous endocannabinoids may provide a new drug target for treating 
psychiatric disorders using reconsolidation-based therapies. Growing evidence indicates a fundamental role 
for the endocannabinoid system in regulating memory consolidation (Campolongo et al, 2009; Hauer et al, 
2011). However, less is known about endocannabinoid signaling in reconsolidation (De Oliveira Alvares et 
al, 2008; Kobilo et al, 2007), especially within the amygdala (Bucherelli et al, 2006; Lin et al, 2006). 
Furthermore, the involvement of endocannabinoid signaling in the reconsolidation process may not be 
straightforward, with apparently conflicting results having been reported in the literature: while agonism 
and antagonism at endocannabinoid receptors (CBRs) bidirectionally modulates the reconsolidation of 
aversive memories by respectively enhancing and impairing memory (De Oliveira Alvares et al, 2008; Suzuki 
et al, 2008), the CBR agonist, WIN55,212-2 impairs reconsolidation in fear-potentiated startle procedures 
after CS re-exposure (Lin et al, 2006). Treatment with the CBR subtype 1 (CB1R) antagonist rimonabant 
neither enhanced pavlovian fear memory nor resulted in amnesia (Suzuki et al, 2004); however, rather than 
indicating that reconsolidation is not dependent on CB1Rs, these data may instead reflect a requirement for 
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CB1Rs in the destabilization of memory (Suzuki et al, 2008). As the effects of blocking the restabilization of a 
reconsolidating memory can only be seen when memory destabilization has occurred (Ben Mamou et al, 
2006; Milton et al, 2013), we hypothesized that the timing of the endocannabinoid manipulation may be 
critical in determining the behavioral outcome of the memory manipulation; we therefore predicted that if 
endocannabinoid signaling manipulations can disrupt memory destabilization or restabilization depending 
on treatment timing, amnesia would only be observed if the endocannabinoid system was targeted after 
memory reactivation. This is critically important for the future translation of reconsolidation-based 
therapies to the clinic. 
 
Here, we have employed the widely-used pavlovian fear conditioning rodent model of PTSD that 
encompasses some of its key behavioural and physiological symptoms (Dębiec and LeDoux, 2004; Johansen 
et al, 2011; Mahan and Ressler, 2012) to test the hypotheses that: (i) the restabilization of an auditory fear 
memory would only be impaired if cannabinoid compounds were given following a memory reactivation 
session; (ii) that memory restabilization would be enhanced by increasing endocannabinoid signaling, (iii) 
that the requirement for endocannabinoids in reconsolidation would depend upon GABAergic transmission 
in the BLA. To investigate the necessity of CB1R activation for mnemonic processes, we used the CB1R 
antagonist AM251. However, as the use of drugs that directly bind and activate brain CBRs, such as 
WIN55,212-2 administered systemically, may ultimately be precluded from human clinical use by their 
abuse liability (Fattore et al, 2001), we chose to use the fatty-acid amide hydroxylase (FAAH) inhibitor 
URB597 (URB), which increases endogenous cannabinoid levels, which has no rewarding or reinforcing 
effects when given systemically (Piomelli et al, 2006). Therefore, animals with a well-consolidated auditory 
fear memory were infused with either URB or the CB1R antagonist AM251 (AM) into the BLA, either before 
or after fear memory reactivation. As endocannabinoids are hypothesized to regulate GABAergic signaling 
within the BLA (Azad et al, 2004), particularly at the GABAA-subtype of receptor (Katona et al, 2001), we 
also investigated whether antagonism at GABAergic receptors could rescue any memory deficit induced by 
CB1R blockade. 
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MATERIALS AND METHODS 
Subjects 
122 male Lister-Hooded rats (300-320g at the time of surgery, Charles River, Bicester, UK) were pair-housed 
on a reversed light-dark cycle (lights on at 1900 hrs). All subjects were fed 25 g per rat after behavioral 
procedures each day starting from the day of surgery; this amount of food maintains animals at a weight 
comparable to animals that receive food ad libitum. Water was available ad libitum except during the 
behavioral and infusion procedures. All procedures were conducted in accordance with the UK Animals 
(Scientific Procedures) Act 1986. 
Surgery 
Rats were anesthetized with a mixture (i.m.) of ketamine (80mg kg-1; Ketaset, Pfizer, Walton-on-the-Hill, UK) 
and xylazine (10mg kg-1; Rompun, Bayer, Newbury, UK) and implanted with bilateral guide cannulae (16mm, 
24 gauge; Coopers Needle Works Ltd, Birmingham, UK) just dorsal to the BLA, as described previously 
(Milton et al, 2008) with co-ordinates of AP - 2.6 mm and ML ± 4.5 mm (from bregma), and DV – 5.6 mm 
(from dura). Stainless steel obdurators (Coopers Needle Works Ltd.) were inserted into both cannulae to 
maintain patency. A recovery period of at least 7 days was given prior to behavioral testing.  
Drug infusions 
Drugs were infused into the BLA using a syringe pump (Harvard Apparatus, Edenbridge, UK) and 5 μl 
Hamilton syringes, connected to injectors (28 gauge, projecting 2 mm beyond the guide cannulae; Bilaney, 
Sevenoaks, UK) by polyethylene tubing. All infusions were begun 30 seconds after the insertion of the 
injectors and performed over 2 minutes at a rate of 0.25 μl per min (total volume of 0.5 μl per side). The 
injectors were left in place for a further minute after the end of the infusion to allow the drugs to diffuse 
from the injection site. Although it is anticipated that the effects of infusions delivered at this rate and 
volume should be largely restricted to the BLA, we cannot exclude that the compounds may have also 
affected other amygdala nuclei. URB597 (Mor et al, 2004), a fatty-acid amide hydroxylase (FAAH) inhibitor 
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(URB; cyclohexylcarbamic acid 3´-carbamoyl-biphenyl-3-yl ester, 30 ng per 0.5 μl per side, Sigma-Aldrich, 
Dorset, UK), the CB1R antagonist AM251 (Lan et al, 1999; AM; N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-
dichlorophenyl)-4-methyl-1H-pyrazole-3 carboxamide, 300 ng per 0.5 μl per side, Tocris, Bristol, UK) and 
GABAA receptor antagonist 1(S),9(R)-(−)-Bicuculline methiodide (BIC; 50 ng per 0.5 μl per side, Sigma-
Aldrich) were dissolved in a vehicle (VEH) containing 5% polyethylene glycol, 5% Tween-80 and 90% saline. 
Dose-response curves for these drugs in fear memory tasks have been reported previously in the literature, 
so the doses used in the current work were chosen based on previous studies: the URB dose used is higher 
than the dose required to enhance the consolidation of inhibitory avoidance (IA) memory (Campolongo, 
2010; Ratano et al, 2011); the AM dose is within the range that impairs olfactory fear conditioning (Tan et 
al, 2011) and higher than the dose that impairs the consolidation of IA memory (Campolongo et al, 2009); 
the dose of BIC impairs the consolidation of IA memory (Dickinson-Anson and McGaugh, 1997) and also the 
extinction of contextual fear memory (Berlau and McGaugh, 2006).  
Histology 
After behavioral testing was completed, rats received an overdose of sodium pentobarbital (Dolethal; 
Rhone-Merieux, Harlow, UK) and were transcardially perfused with 0.01 M PBS, followed by 4% 
paraformaldehyde (PFA). Brains were collected and stored in 4% PFA for at least 24 hours, before being 
transferred to 20% sucrose solution for cryoprotection prior to sectioning. The brains were sectioned 
coronally at 60 μm, stained with Cresyl Violet, and the cannulae placement assessment was conducted 
under light microscopy (Leica). Only subjects with the injectors located bilaterally within the BLA, and with 
no bilateral damage to the amygdala or any other area of the brain were included in the statistical analysis 
(Figure 1). 
Behavioral procedures 
Auditory fear conditioning was performed similarly to as described previously (Lee et al, 2005; Lee et al, 
2006; Milton et al, 2013). Briefly, on Day 1, rats were habituated to the conditioning chamber (Med 
Associates, Sandown Scientific, Hampton, UK) for 2 hours and allowed to freely explore the context. On Day 
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2, the rats were placed in the same experimental context, and conditioned with two CS-US pairings. The CS 
was an auditory clicker (10 Hz, 80 dB, 60 s) and the US an electric footshock (0.5 mA, 1 s). The first CS-US 
pairing was presented after 35 ± 1 minute from the start of the session, followed by a 5 ± 1 minute interval 
when a second CS-US pairing was given. The conditioning session terminated 5 minutes after the last 
footshock delivery.  
On Day 3, the fear memory was reactivated by re-exposing the rats to the conditioning chamber for a 2-min 
session, to a single presentation of the 60 s CS after 60 s of context exposure. All rats received an intra-BLA 
infusion of drug 30 minutes before or immediately (1-5 minutes) after the memory reactivation session. The 
timing of the pre-reactivation infusions was based on previous studies, where URB597 enhances stress-
induced analgesia when administered intracranially 35 minutes prior to test (Hohmann et al, 2005) and 
AM251 blocks the effects of CB1R agonism on the tail flick test for at least an hour after intracranial infusion 
(Hasanein et al, 2007). Non-reactivated control groups underwent the same behavioral procedures, except 
that, on Day 3, the drug infusions were given in a novel room and they were not re-exposed to either the 
training context or the CS. 
Testing took place 24 h (post-reactivation long-term memory, PR-LTM24h) and 8 days (PR-LTM8d) after 
reactivation to test long-term memory retention. Animals were returned to the conditioning chambers for a 
2-min session where they received a single presentation of the 60-s CS after 60 s of context exposure. 
Freezing behavior was video-recorded, and conditioned freezing scored offline by an experimenter blind to 
treatment. Freezing is defined as the lack of movement except for breathing, and was assessed at 5 s 
intervals to give the percentage of time freezing. Freezing during the first minute of the testing session was 
assessed as measure of fear to the experimental context, and during the second as measure of fear to the 
CS. 
Statistical Analysis 
Data are presented as the mean ± s.e.m. and were analyzed using repeated measures ANOVA, with CS 
(Context vs. Cue) and Session (Reactivation vs. PR-LTM24hvs. PR-LTM8d) as within-subject factors, and Drug 
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(VEH vs. URB vs. AM) as between-subjects factors. Where the data violated the assumption of sphericity as 
assessed using Mauchly’s test, a correction was applied; the Greenhouse-Geisser correction if ε < 0.75, and 
the Huynh-Feldt correction if ε > 0.75, as recommended by Cardinal & Aitken (2006). Where appropriate, 
further ANOVAs or pairwise comparisons were conducted; all pairwise comparisons were adjusted using the 
Šidák correction, which is a mathematically accurate form of the Bonferroni estimation (Cardinal et al, 
2006). 
 
RESULTS 
Pre-reactivation infusion of URB597 and AM251 affected neither retrieval nor reconsolidation of 
pavlovian fear memory 
In the first experiment, the FAAH inhibitor URB597 (URB) or the CB1R antagonist AM251 (AM) or vehicle 
(VEH) were bilaterally infused into the BLA 30 minutes prior to memory reactivation. All experimental 
groups had previously conditioned to the CS, as all rats showed a greater freezing response to the CS than 
to the context during the reactivation session [F1,25=41.6, p<0.001, η2=0.63]. As shown in Figure 2, rats in all 
experimental groups froze similarly to the CS during the test sessions [Drug: F<1], and though conditioned 
freezing reduced across the test sessions [Session: F2,50 =5.83, p=0.005, η2=0.19], this extinction was the 
same for all experimental groups [F<1]. Furthermore, analyzing the memory reactivation session alone 
showed that there were no acute effects of the drugs on the expression of conditioned freezing [F<1]. Thus, 
neither URB nor AM affected memory retrieval or reconsolidation when given prior to memory reactivation. 
 
AM251 infused immediately post-reactivation disrupted, whereas URB597 slightly and transiently 
enhanced, fear memory reconsolidation 
AM infused into the BLA immediately after memory reactivation disrupted fear memory reconsolidation as 
assessed at test (Figure 3). All rats had previously conditioned to the CS, and all groups showed a greater 
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fear response to the CS than to the context during the reactivation session [F1,29=50.5, p<0.001, η2=0.64]. 
However, animals that received AM immediately post-reactivation showed less freezing at test, 24h later, 
than animals receiving URB or VEH [Drug: F2,29= 6.00, p<0.01, η2=0.29] across both test sessions [Session: 
F2,29=4.78, p<0.05, η2=0.14] and all experimental groups [Drug x Session: F4,58=5.53, p<0.001, η2=0.28]. Rats 
infused with AM immediately after the reactivation session froze less at test 24h after reactivation than 
they had during the reactivation session [PR-LTM24h vs. reactivation, p=0.011; PR-LTM8d vs. reactivation, 
p=0.001]. 
 
Rats infused with URB post-reactivation showed higher levels of freezing at the 24h test than they had 
shown during the memory reactivation session [PR-LTM24h vs. reactivation, p=0.041], but this increased 
fear response to the CS did not persist to the 8d test [PR-LTM8d vs. reactivation, p=0.96]. Thus, intra-BLA 
infusion of URB may have produced a small, transient enhancement of memory reconsolidation, while the 
antagonist AM persistently disrupted reconsolidation of pavlovian fear memory. 
 
The effects of intra-BLA AM251 and URB597 on memory reconsolidation were dependent on memory 
reactivation 
To determine whether the effects of URB and AM on fear memory persistence were reactivation-
dependent, separate groups of rats were infused with URB, AM or VEH, without undergoing memory 
reactivation (Figure 4). All rats previously conditioned to the CS, as they froze more during the CS 
presentation than to the context 48h after conditioning [F1,21= 23.5, p<0.001, η2=0.53]. Though the 
experimental groups did not differ from each other [Drug: F2,21=0.02, p=0.98], the URB-infused group did 
not extinguish responding across the two test sessions, unlike the AM and VEH groups [Drug x Session: 
F2,21=4.57, p<0.05, η2=0.30]. While there was a reduction in freezing at the 8d test for animals infused with 
VEH [PR-LTM24h vs. PR-LTM8d, p<0.05] and AM [PR-LTM24h vs. PR-LTM8d, p<0.01], the URB-treated 
animals did not reduce their freezing behavior [PR-LTM24h vs. PR-LTM8d, p > 0.05]. Furthermore, the non-
reactivated AM-treated group showed greater freezing at the 24hr test than animals that had received AM 
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following memory reactivation [Figure 3; p<0.05] indicating that the amnesia produced by AM was 
reactivation-dependent. Thus, 48h and 9d after conditioning, the fear memory was still intact, and the 
amnesia produced by AM was only seen when the drug was given in conjunction with memory reactivation. 
 
The disruption of reconsolidation produced by AM251 was blocked by the administration of the GABAA 
receptor antagonist bicuculline 
In order to better understand the persistent amnesia produced by post-reactivation AM administration, we 
investigated the interaction of endocannabinoid and GABAergic signaling within the amygdala. To test the 
hypothesis that the amnesia produced by the CBR antagonist AM was mediated by increased GABA 
transmission, animals were infused with the GABAA receptor antagonist bicuculline (BIC), alone or in 
conjunction with AM at reactivation (Figure 5). As before, all rats previously conditioned to the CS, and 
froze more during the CS presentation than to the context during the reactivation session [F1,34=184.0, 
p<0.001, η2=0.84]. All rats showed equivalent levels of freezing during the reactivation session [F3,34=1.27, 
p=0.30] and AM infusions post-reactivation resulted in amnesia at tests 24h later [Drug: F3,34=3.12, p<0.05, 
η2=0.22; Session: F2,68=55.5, p<0.001, η2=0.62; Session x Drug: F6,68=4.31, p<0.001, η2=0.28] though 
administration of BIC alone had no effect relative to VEH [p > 0.99]. Freezing was reduced at test relative to 
reactivation for rats that had received either AM [PR-LTM24h vs. reactivation, p<0.001; reactivation vs. PR-
LTM8d, p<0.001], BIC alone [PR-LTM24h vs. reactivation, p=0.011; PR-LTM8d vs. reactivation, p=0.001] or 
AM+BIC [PR-LTM8d vs. reactivation, p=0.002]. Post hoc tests showed that at test, AM-treated rats froze less 
than VEH-treated [p=0.029] and BIC-treated rats [p=0.017] and, importantly, less than animals receiving 
AM+BIC [p=0.045]. Thus, the disruptive effect on memory reconsolidation induced by the blocking CB1Rs 
was replicated, and this disruption of reconsolidation could be prevented by antagonism at GABAA 
receptors. These results indicate that the endocannabinoid signaling-mediated disruption of CS-fear 
memory reconsolidation depends upon the consequent increase in GABAergic transmission in the BLA.  
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DISCUSSION 
We have demonstrated that antagonism at CB1Rs prevents fear memory reconsolidation and may offer a 
promising therapeutic strategy in the treatment of post-traumatic stress disorder (PTSD), while also 
elucidating the mechanism by which CB1R antagonism exerts its effects on anxiety. Although there are 
other animal models, such as the single-prolonged stressor, predator-based psychosocial stress and 
predator scent stress models (see Daskalakis et al, 2013, for review) that capture different aspects of PTSD, 
we have shown that blocking CB1Rs within the BLA disrupted the reconsolidation of a pavlovian CS-fear 
memory, resulting in persistent loss of fear evoked by the subsequent presentation of the CS, a change in 
behavior widely suggested to model a desirable outcome for PTSD treatment (Dębiec and LeDoux, 2006; 
Parsons and Ressler, 2013; Schiller et al, 2010). This disruption of memory reconsolidation, which persisted 
for at least 8d after CS re-exposure, occurred if and only if the CB1R antagonist AM251 was infused locally 
in BLA immediately after retrieval; administration 30 minutes prior to memory reactivation did not result in 
an amnestic effect during the test sessions, and AM251 administration in the absence of memory 
reactivation did not produce amnesia. Non-reactivated groups tended to show lower levels of conditioned 
fear at test than animals that had been reactivated, supporting the hypothesized function for 
reconsolidation of memory strengthening. However, although freezing was reduced in the non-reactivated 
groups, it was still higher than in amnesic animals; therefore, the requirement for AM251 treatment and 
reactivation is more consistent with a blockade of memory restabilization than insensitivity of 
measurement. By contrast to the amnesia produced by AM251 given after reactivation, infusion into the 
BLA of the FAAH inhibitor URB597 in conjunction with memory reactivation resulted in a minor, transient 
enhancement of conditioned freezing. Whether a greater – or more sustained – effect would be observed 
with a higher dose of URB597 remains to be established, though it should also be considered that drugs 
targeting the endocannabinoid system often have biphasic effects (Metna-Laurent et al, 2012). 
Furthermore, we found that the memory impairment induced by post-reactivation CB1R antagonism could 
be prevented by co-infusion of the GABAA receptor antagonist bicuculline, suggesting that 
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endocannabinoid-mediated signaling affects reconsolidation via modulation of GABAergic transmission in 
the amygdala. 
 
The data presented here are consistent with previous work indicating a role for CB1Rs in the plasticity 
underlying emotional memory, and help to account for some of the apparent inconsistencies in the 
previous literature. CB1Rs are required for the extinction, though interestingly not the consolidation 
(Arenos et al, 2006; Marsicano et al, 2002), of conditioned fear memory for context-shock associations 
(Suzuki et al, 2004) and tone-shock associations (Marsicano et al, 2002) and enhancing CB1R transmission 
enhances the extinction of fear memory (Chhatwal et al, 2005). However, while it has previously been 
shown that antagonists at CB1Rs disrupt the consolidation of inhibitory avoidance memory (Campolongo et 
al, 2009), consolidation of contextual fear conditioning is impaired by the activation of CB1Rs within the 
hippocampus (Maćkowiak et al, 2009). We hypothesize that these apparently discrepant findings are due to 
the timing of the amnestic treatment. We suggest that CB1Rs are required for the process of memory 
destabilization, as has been shown for contextual fear memories (Suzuki et al, 2008). Although extinction is 
usually conceptualized as the learning of a new, inhibitory ‘CS-no US’ memory (Bouton, 1991), there is 
evidence that there are some changes in synaptic strength in the amygdala, which are required for long-
term storage of the original CS-fear memory (Gale et al, 2004), following extinction training (see Barad et al, 
2006, for review). Our finding that blocking CB1Rs prior to memory reactivation did not result in amnesia is 
consistent with the blockade of memory destabilization (Suzuki et al, 2008) which, it should be noted, is a 
process that is doubly dissociable from memory retrieval (Milton et al, 2013). Blockade of memory 
destabilization would prevent memory reconsolidation from being engaged, and consequently prevent the 
effects of any treatment that might enhance (e.g. FAAH) or disrupt (e.g. AM251) reconsolidation (Lee, 
2008). Mechanistically, this effect may be mediated through indirect actions on BLA pyramidal neurons. 
CB1Rs are located on GABAergic interneurons within the BLA (Katona et al, 2001) and act presynaptically to 
reduce GABAergic transmission onto BLA pyramidal neurons (Azad et al, 2003; Katona et al, 2001). Thus, we 
hypothesize that CB1R antagonism should act to disinhibit GABAergic interneurons, increasing the inhibition 
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of the pyramidal neurons, and therefore preventing the neuronal activity, mediated through GluN2B-
containing NMDARs (Milton et al, 2013), that is required for memory destabilization. This is a speculative 
hypothesis and the interactions between endocannabinoid and glutamatergic signaling in fear memory 
reconsolidation remain to be investigated.      
 
When administered after memory reactivation, CB1R antagonism led to a blockade of memory 
restabilization that was dependent on GABAergic signaling. We hypothesize that after memory reactivation, 
when the destabilization process has already occurred, the disinhibition of GABAergic interneurons through 
CB1R antagonism acts again to inhibit pyramidal neurons, but this time largely affecting GluN2A-containing 
NMDARs, which are required for memory restabilization (Milton et al, 2013). Thus, CB1R antagonism should 
result in amnesia similar to that observed following the administration of drugs that enhance GABAergic 
signaling (Zhang and Cranney, 2008). This hypothesis is supported by our finding that antagonism at GABAA 
receptors rescued the AM251-induced deficit. Unlike previous work, we did not observe amnesia when BIC 
was administered alone; however, previous work targeting GABAergic signaling in reconsolidation (Bustos 
et al, 2006; Zhang et al, 2008) has used systemic administration of GABAergic receptor antagonists rather 
than intracerebral infusions, as were used here. Furthermore, whether the transient memory enhancement 
produced by URB597 administration is also dependent upon GABAergic mechanisms remains a subject for 
future research. 
  
We would argue that an alternative view – that the time dependence of the manipulation was simply due to 
the drugs being ineffective during the memory reactivation session when administered 30 minutes 
beforehand – is unlikely, as both URB597 and AM251 have been shown to produce behavioral effects when 
administered intracranially at earlier time points relative to the behavioral session (Hasanein et al, 2007; 
Hohmann et al, 2005). Therefore, we suggest that the difference in the effects of CB1R antagonism – 
impairing destabilization or restabilization of the fear memory – depends more critically upon treatment 
timing.  
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There has been much discussion about the timing of administration of amnestic agents relative to memory 
reactivation in studies of reconsolidation (Finnie and Nader, 2012; Schiller and Phelps, 2011). We suggest 
that there is no theoretical requirement for treatment timing that determines whether reconsolidation is 
targeted or not; instead, the focus should be on whether the process of memory destabilization or 
restabilization is being targeted. Some amnestic agents, such as non-subtype selective NMDA receptor 
antagonists, prevent memory restabilization but not destabilization (Lee et al, 2006; Milton et al, 2008; 
Milton et al, 2013) and pre-reactivation administration is more effective than post-reactivation 
administration because NMDA receptor antagonism results in amnesia by blocking fast excitatory 
neurotransmission events at the point of reactivation. For other amnestic agents, such as protein synthesis 
inhibitors (Milekic and Alberini, 2002; Nader et al, 2000), where the onset of the process to be inhibited is 
slower, post-reactivation administration is effective at disrupting restabilization. In this context, the effects 
of manipulating endocannabinoid signaling are unusual and of particular interest, because they can result in 
opposite effects on memory processes depending on the timing of antagonist administration. For example, 
for the consolidation of inhibitory avoidance memory, blocking CB1Rs in rat hippocampus and BLA with 
AM251 post-training induces impairments in avoidance behavior (De Oliveira Alvares et al, 2008), but pre-
training administration of AM251 facilitates consolidation (De Oliveira Alvares et al, 2008). A better 
understanding of the molecular mechanisms that underlie memory destabilization and restabilization, and 
how they interact with different neurotransmitter systems, such as the endocannabinoid system, will be 
more beneficial to future reconsolidation studies and translation to the clinic than assertions that all 
treatments must be given post-reactivation in order to avoid effects on the separate and dissociable 
process of memory retrieval. 
 
The data presented here clarify the requirement for endocannabinoid signaling in memory reconsolidation, 
and also indicate a novel target for the disruption of maladaptive memories that contribute to the 
persistence of psychiatric disorders such as PTSD (Brewin et al, 1996). Although additional investigations in 
 15 
 
other animal models of PTSD, and with systemic administration of the compounds used here, would be 
informative and would facilitate translation to the clinic, our data indicate that antagonizing CB1Rs after 
memory reactivation may allow the disruption of old, well-established fear memories, reducing the 
persistence of the physiological and behavioral anxiety symptoms that characterize PTSD. 
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FIGURE LEGENDS 
Figure 1. Representation of cannulae placements within the BLA. The placements for individual 
experiments are shown separately, and coordinates are from bregma. For each experiment (A, pre-
reactivation administration; B, post-reactivation administration; C, administration without reactivation; D, 
combined endocannabinoid and GABAergic manipulations) the white circles represent the vehicle group 
and the dark circles represent the AM group. The gray circles represent URB group (A, B, C), the gray 
squares represents the BIC group (D), and the dark squares represent AM+BIC group (D). This figure was 
modified, with permission, from Paxinos and Watson (2004). 
 
Figure 2. Effects of the FAAH inhibitor URB and the CB1 receptor antagonist AM on CS–fear memory 
reconsolidation. Administration of URB or AM prior to memory reactivation had no effect on the retrieval of 
the CS–fear memory at reactivation and did not alter expression of freezing response at tests conducted 
24h or 8d later. Group sizes were VEH, n=9; URB, n=10; AM, n=9. 
 
Figure 3. Effects of the FAAH inhibitor URB597 (30ng/0.5μl) and the CB1 receptor antagonist AM251 
(300ng/0.5μl) on CS–fear memory reconsolidation. Administration of URB597 (30ng/0.5μl) immediately 
after the reactivation session produced a small, transient enhancement of CS–fear memory reconsolidation 
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at 24h, but not 8d, after reactivation. AM251 (300ng/0.5μl) persistently impaired memory reconsolidation 
when compared with vehicle and URB597 (30ng/0.5μl)-treated rats after both 24h and 8d after the 
reactivation session. Data are presented as means ± SEM. Group sizes were VEH, n=10; URB597 
(30ng/0.5μl), n=12; AM251 (300ng/0.5μl), n=10. 
 
Figure 4. Effects of the FAAH inhibitor URB597 (30ng/0.5μl) and the CB1 receptor antagonist AM251 
(300ng/0.5μl) on CS–fear memory reconsolidation in rats not exposed to the memory reactivation session. 
Administration of URB597 (30ng/0.5μl) or AM251 (300ng/0.5μl) in absence of memory reactivation had no 
effect on the retrieval of the CS–fear memory both 24h and 8d after administration. Data are presented as 
means ± SEM. Group sizes were VEH, n=8; URB597 (30ng/0.5μl), n=8; AM251 (300ng/0.5μl), n=8. 
 
Figure 5. Effects of the CB1 receptor antagonist AM251 (300ng/0.5μl) or the GABAA receptor antagonist 
bicuculline (BIC 50ng/0.5μl) on CS–fear memory reconsolidation. Administration of AM251 (300ng/0.5μl) 
immediately after the reactivation session persistently impaired the CS–fear memory both 24h and 8d after 
the reactivation session. Data are presented as means ± SEM. Group sizes were VEH, n=10; AM251 
(300ng/0.5μl), n=10; BIC (50ng/0.5μl), n=10; AM251 (300ng/0.5μl) + BIC (50ng/0.5μl), n=8. 
 





